GlassScriptPhysician profile
Lilit Minasyan
NPI 1861861932
$4,685.18
in general payments reported to CMS, 2019-2025
24 companies · $901 in 2025
The $901 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $736 · 2021: $412 · 2022: $569 · 2023: $458 · 2024: $735 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Entertainment: $21.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.98 |
| Entertainment | $21.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $963.54 | 2019-2021 | |
| Alcon Vision LLC | $678.44 | 2019-2025 | Centurion, Hydrus Microstent, Rocklatan |
| Sight Sciences, INC. | $580.28 | 2021-2024 | Omni Surgical System |
| New World Medical,INC. | $379.85 | 2023-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Novartis Pharmaceuticals Corporation | $367.96 | 2019-2021 | |
| Abbvie INC. | $288.50 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $228.23 | 2021-2025 | Cequa, Xelpros, Bromsite |
| Dompe US, INC. | $195.63 | 2022-2025 | Oxervate |
| Allergan, INC. | $166.05 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $158.77 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Glaukos Corporation | $125.00 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $95.41 | 2025 | Xdemvy |
| Amgen INC. | $79.98 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $76.63 | 2022-2024 | Tyrvaya |
| Janssen Pharmaceuticals, INC | $59.50 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $54.18 | 2025 | Vevye |
| Horizon Therapeutics Plc | $32.96 | 2023 | Tepezza |
| Thea Pharma INC. | $31.06 | 2023-2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $25.95 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Shire North American Group INC | $24.63 | 2019 | |
| Akorn, INC. | $21.68 | 2019 | |
| Optos, INC. | $21.36 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Rxsight INC | $17.77 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilit Minasyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.